Report
Reality check: New drugs will cost more
The trend toward complex biologic drugs continues
By Sumit Dutta, MD, Chief Medical Officer at Optum Rx | Published: July 2022
What's in the pipeline?
This Optum Rx Drug Pipeline Report issue highlights four drugs reflecting cutting-edge technologies and their expected approval times:
- Multiple myeloma
- Plaque psoriasis
- Two gene therapy drugs that target ultra-rare orphan conditions
Don't want to read the full report? Download the brief summary.
Related content
Will these 4 new drugs re-shape the market?
Get the latest in this quarter’s Drug Pipeline Insights Report.
Rush to judgement?
An inside look at the FDA's prescription drug approval process.
Will Diabetes Drugs Help Us Tackle Obesity?
Discover four things to know about new uses of GLP-1 drugs.
Top